NASDAQ:EGRX Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis $0.90 -0.39 (-29.96%) As of 09/23/2026 02:52 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesNews and TrendsSEC Filings About Eagle Pharmaceuticals Stock (NASDAQ:EGRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eagle Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.18▼$0.9050-Day Range$0.05▼$1.2952-Week Range$0.00▼$3.00Volume294 shsAverage Volume7,847 shsMarket Capitalization$11.69 millionP/E Ratio0.76Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing injectable products for use in hospital and other acute-care settings. The company’s portfolio includes branded products, ready-to-use formulations and therapies designed to address clinical or logistical challenges associated with existing medicines. Eagle’s marketed products have included Ryanodex (dantrolene sodium), an emergency treatment for malignant hyperthermia; Belrapzo (bendamustine hydrochloride), used in certain blood cancers; Pemfexy (pemetrexed), a chemotherapy treatment; Barhemsys (amisulpride), used to prevent and treat postoperative nausea and vomiting; and Byfavo (remimazolam), an intravenous sedative used for procedural sedation. Product availability and commercialization arrangements may change over time. Founded in 2007, Eagle Pharmaceuticals has primarily served the U.S. healthcare market through hospitals, oncology practices and other institutional-care providers. The company has historically emphasized products that improve dosing convenience, reduce preparation requirements or offer alternatives to established injectable medicines. Scott Tarriff, a co-founder of Eagle, has served as the company’s chief executive officer and has been a prominent member of its leadership.AI Generated. May Contain Errors. Read More Receive EGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EGRX Stock News HeadlinesEagle Pharmaceuticals (NASDAQ:EGRX) Share Price Passes Below 50-Day Moving Average - Time to Sell?September 22 at 4:20 AM | americanbankingnews.comEagle Pharmaceuticals Inc.August 27, 2026 | marketwatch.comWhat the Iran War Is Really AboutTwo thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets. | Behind the Markets (Ad)Did Eagle Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?April 9, 2026 | prnewswire.comEagle Pharmaceuticals Announces Divestiture of BarhemsysJanuary 14, 2026 | globenewswire.comHALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSDecember 24, 2025 | prnewswire.comHalper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their RightsDecember 7, 2025 | businesswire.comEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights PlanOctober 30, 2025 | finanznachrichten.deSee More Headlines EGRX Stock Analysis - Frequently Asked Questions How have EGRX shares performed this year? Eagle Pharmaceuticals' stock was trading at $0.70 on January 1st, 2026. Since then, EGRX stock has increased by 28.6% and is now trading at $0.90. How were Eagle Pharmaceuticals' earnings last quarter? Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to analyst estimates of $46.70 million. How do I buy shares of Eagle Pharmaceuticals? Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eagle Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eagle Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), ExxonMobil (XOM), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/09/2021Today9/23/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:EGRX CIK827871 Webwww.eagleus.com Phone(201) 326-5300FaxN/AEmployees100Year Founded2007Profitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio0.76 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$257.55 million Price / Sales0.05 Cash Flow$2.25 per share Price / Cash Flow0.40 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares12,987,000Free Float9,234,000Market Cap$11.69 million OptionableNo Data Beta0.83 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:EGRX) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhat the Iran War Is Really AboutTwo thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredAmazon's touch-enabled robot points to AI's next phaseAmazon wants touch-enabled robots to handle 80% of work across roughly 14 billion warehouse items a year. One ...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
